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CASE REPORT
CLINICAL CASE SERIES

Cardiogenic Shock Due to Atrial
Arrhythmia as the Initial Presentation of
Transthyretin Cardiac Amyloidosis
Svenja M. Schneider, MD,a Kirpal Kochar, MD,a Max Ruge, MD,a Stefanie Marek-Iannucci, MD,b Tanuka Datta, MD,b
Alexander Hajduczok, MD,b Waqas Ullah, MD,b Indranee Rajapreyar, MD,b Yevgeniy Brailovsky, DOb

ABSTRACT
Atrial arrhythmias are common in transthyretin cardiac amyloidosis (ATTR-CA), with a prevalence of #80%. They are
often not well tolerated. We describe 3 patients with decompensated heart failure and cardiogenic shock precipitated by
atrial arrhythmias who ultimately received diagnoses of ATTR-CA. (Level of Difﬁculty: Intermediate.)
(J Am Coll Cardiol Case Rep 2022;4:1490–1495) © 2022 The Authors. Published by Elsevier on behalf of the American
College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).

T

ransthyretin cardiac amyloidosis (ATTR-CA)

In this clinical case series, we describe 3 patients

is an inﬁltrative process characterized by the

who presented with acute decompensation and

deposition of amyloid ﬁbrils in the myocar-

cardiogenic shock precipitated by atrial arrhythmias

dium, resulting in a restrictive cardiomyopathy.
Historically, ATTR-CA has been under-recognized
because of its variable clinical presentation. Atrial
ﬁbrillation has a prevalence of 60% to 80% in ATTRCA.1-4 Owing to impaired atrial ﬁlling, atrial arrhyth-

mias are generally not well tolerated in patients with
cardiac amyloidosis. This leads to dependence on
heart rate to maintain cardiac output (CO), which can
manifest as cardiogenic shock.

LEARNING OBJECTIVES
 To recognize ATTR-CA in acute decompensated heart failure precipitated by atrial
arrhythmias with signs of restrictive physiology or lack of expected ventricular dilation
on echocardiogram.
 To understand the unique challenges of
managing atrial arrhythmias in ATTR-CA.

in the setting of previously unrecognized ATTR-CA.

CASE PRESENTATIONS
PATIENT

1. An 86-year-old man

presented with

1 month of worsening dyspnea and lower extremity
edema. An initial electrocardiogram (ECG) revealed
new atrial ﬂutter with a ventricular rate of 108 beats/
min (Figure 1A). On admission, N-terminal pro b-type
natriuretic peptide was 8,456 pg/mL, and creatinine
was 1.8 mg/dL from 1.3 mg/dL previously.
A transthoracic echocardiogram (TTE) showed a
small left ventricular (LV) cavity (LV end-diastolic
diameter [LVEDD] 3.8 cm) with severely decreased
LV systolic function and global hypokinesis (ejection
fraction [EF] 10%) and global longitudinal strain of
5.1% with apical sparing (Figure 2). The LV outﬂow
velocity time integral was severely reduced at 7 cm
(normal >18 cm) with an estimated stroke volume of
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16 mL and a severely reduced estimated cardiac

rhythm

output of 1.7 L/min (normal 4-6 L/min). LV function

outpatient follow-up 1 month later. Repeated

had been normal on TTE 1 year prior with an EF of 51%.

TTE 6 months after hospitalization showed

Although he improved clinically with intravenous

an improvement in LV systolic function with

and

clinically

compensated

on

ABBREVIATIONS
AND ACRONYMS
ATTR-CA = transthyretin
cardiac amyloidosis

diuresis, he was intolerant of any guideline-directed

an EF of 69%.

medical therapy because of hypotension. His heart

PATIENT 3. A 68-year-old woman with a

rate remained stable, under 100 beats/min. Severely

history of left bundle branch block presented

reduced systolic function without compensatory LV

with progressive dyspnea, weakness, and

dilation and intolerance to guideline-directed medi-

palpitations. Her ECG revealed atrial tachy-

cal therapy caused concern about the potential for

cardia with a ventricular rate of 170 beats/min

underlying cardiac amyloidosis. A pyrophosphate

(Figure 1C). Her serum lactate was 3.0 mmol/

(PYP) scan conﬁrmed our suspicion, with grade 3

L, and N-terminal pro b-type natriuretic

uptake and a heart-to-contralateral ratio of 1.97,

peptide was 4,304 pg/mL. TTE showed severe

consistent with ATTR-CA (Figure 2). The result of

biatrial enlargement, severely decreased LV

evaluation for light chain amyloidosis was negative.

systolic function with global hypokinesis (LVEDD

The result of gene testing for TTR gene was negative.

5.3 cm, LV EF 10%), and global longitudinal strain of

He was given tafamidis and apixaban for stroke pre-

4.7%. Milrinone was initiated, with improvement in

vention. The patient declined transesophageal echo-

end-organ function, and amiodarone was given, with

cardiogram and direct current cardioversion. Despite

resolution of the atrial tachycardia.

persistent

atrial

compensated

on

ﬁbrillation,
outpatient

he

was

follow-up,

CO = cardiac output
EF = ejection fraction
ECG = electrocardiogram
LV = left ventricle
LVEDD = left ventricular enddiastolic diameter

PYP = pyrophosphate
TTE = transthoracic
echocardiogram

clinically
possibly

F I G U R E 1 Electrocardiograms

because of a relatively well-controlled heart rate of
100 beats/min.
PATIENT 2. An 82-year-old woman with a history of

paroxysmal atrial ﬁbrillation on apixaban and heart
failure with a preserved EF presented with 3 months
of worsening dyspnea and weight gain. ECG revealed
atrial ﬂutter and ventricular rates up to 150 beats/min
(Figure 1B). Initial attempts at rate control with

b-blockers led to worsening cardiogenic shock with a
severely elevated lactate to 7.9 mmol/L, acute kidney
injury with creatinine 3.4 mg/dL from a baseline of
1.2 mg/dL, and oliguria requiring initiation of dobutamine. Her symptoms and laboratory results signiﬁcantly

improved

with
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inotropic

agents

and

intravenous diuresis, and she was eventually weaned
off the inotropic agent.
TTE revealed a normal-sized LV (LVEDD 4.6 cm)
with a reduced systolic function (LVEF 30%). A prior
history of carpal tunnel syndrome in addition to her
clinical presentation raised a suspicion of cardiac
amyloidosis. A PYP scan revealed grade 2 uptake and
a heart-to-contralateral ratio of 1.56 consistent with
ATTR-CA (Figure 3). The results of her work-up for
light chain amyloidosis were mildly abnormal, with a
faint monoclonal l light chain on serum immunoﬁxation and mildly elevated k/l ratio of 2.44, but analysis of a bone marrow biopsy specimen ruled out
plasma cell dyscrasia. Genetic testing conﬁrmed a
Val142Ile variant TTR gene mutation.
The patient underwent successful transesophageal
echocardiogram and direct current cardioversion and
was started on tafamidis. She remained in sinus

(A) Atrial ﬂutter in patient 1. (B) Atrial ﬁbrillation in patient 2. (C) Atrial
tachycardia in patient 3.
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F I G U R E 2 Images of Patient 1

(A) Apical 4-chamber view on echocardiogram with increased LV wall thickness with an interventricular septum thickness of 1.2 cm (asterisk) and low
normal LV internal diameter at end diastole, measuring 3.8 cm. Pyrophosphate scan with single- photon emission computed tomographic image (B)
showing increased myocardial uptake (yellow arrow) and planar image (C) that corresponds to a grade 3 ASNC score and a H/CL of 1.97 (white arrow).

A PYP scan revealed grade 3 uptake and a heart-to-

of ATTR-CA, and we highlight subtle signs that cli-

contralateral ratio of 1.72 consistent with ATTR-CA

nicians may use to unmask unrecognized cardiac

(Figure 4). The result of a work-up for light chain

amyloidosis. Although tachycardia-induced cardio-

amyloidosis was negative. Analysis of an endomyo-

myopathy and related shock are not unique to

cardial biopsy specimen showed results that were

ATTR-CM, there were several clues that raised our

consistent with amyloidosis, and mass spectrometry

clinical suspicion for end-stage ATTR-CA in our pa-

revealed

variant,

tients. They had a newly reduced LV function but

conﬁrmed on genetic testing. She was given tafami-

without compensatory LV dilation, and the ECGs with

dis. Unfortunately, she was unable to be weaned from

relatively low voltage were discordant with increased

inotropic

required

LV wall thickness on TTE (Figure 5). In these cases,

orthotopic heart transplantation. She continues to do

the ﬁndings of decreased EF were most consistent

well after transplantation.

with end-stage ATTR-CA, with high degrees of

ATTR-CA

support,

with

and

an

she

Ala140Se

ultimately

myocardial inﬁltration.

DISCUSSION

The restrictive physiology of ATTR-CA leads to
reliance on heart rate to maintain CO; bradycardia

These 3 cases illustrate how atrial tachyarrhythmias

and tachycardia can lead to a drop in CO. Further-

and cardiogenic shock can be the initial presentations

more,

the

restrictive

physiology

of

ATTR-CA
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F I G U R E 3 Images of Patient 2

(A) Apical 4-chamber view on echocardiogram with increased an interventricular septum thickness of 1.0 cm (asterisk), normal LV dimension
(LVEDD 4.6 cm), and biatrial enlargement. Pyrophosphate scan with single-photon emission computed tomographic image (B) showing
increased myocardial uptake (yellow arrow) and planar image (C) that corresponds to a grade 2 ASNC score and H/CL of 1.56 (white arrow).

increases sensitivity to a loss of organized late dia-

atrial dilation. Given these ﬁndings, increased LV wall

stolic atrial contraction,1 leading to decompensated

thickness, nondilated LV, and atrial arrhythmias in

heart failure and rapid progression to cardiogenic

patients who present with acute heart failure should

shock. Additionally, 50% to 80% of patients with

prompt suspicion of ATTR-CA.

ATTR can have autonomic dysfunction.5 This can

The management of atrial arrhythmias in ATTR-CA

often manifest as impaired compensatory vasocon-

is challenging. There are conﬂicting data on whether

striction and rapid progression to shock, given the

rhythm control is associated with improved survival

impaired ability to increase systemic vascular resis-

in patients with ATTR-CA. 2,4 Furthermore, common

tance to compensate for a decrease in CO.

5

rate-controlling medications such as b -blockers, cal-

There are 2 possible mechanisms for the predis-

cium channel blockers, and digoxin are linked to

position to atrial arrhythmias in ATTR-CA. The ﬁrst is

worse outcomes in ATTR-CA. 7,8 This supports initial

atrial dilation from ventricular wall thickening and

attempts to achieve normal sinus rhythm in these

impaired relaxation from amyloid deposition, causing

patients. The success of antiarrhythmic agents and

elevated ﬁlling pressures. 6 The second is myocardial

direct current cardioversion in ATTR-CA appears to

ﬁbrosis and structural remodeling caused by amyloid

be similar to that in the general population, although

deposition.6 This second mechanism can lead to

more severe ATTR-CA is associated with a higher rate

arrhythmia in the absence of the characteristic left

of recurrence of the arrhythmia. 1,9 The choice of
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F I G U R E 4 Images of Patient 3

(A) Apical 4-chamber view on echocardiogram with increased LV wall thickness with an interventricular septum thickness of 1.3 cm (asterisk),
normal LV dimension, and biatrial enlargement. Pyrophosphate scan with single-photon emission computed tomographic image (B) showing
increased myocardial uptake (yellow arrow) and planar image (C) that corresponds to a grade 3 ASNC score and H/CL of 1.72 (white arrow).

antiarrhythmic agent is often limited because of co-

need for further research on best management stra-

morbid conditions associated with amyloidosis, such

tegies of atrial arrythmias, including rate versus

as

Anti-

rhythm control, cardioversion, and ablation. These

coagulation is an important consideration for patients

cases underscore the importance of maintaining a

with atrial ﬁbrillation and ATTR-CA because the risk

high index of suspicion for ATTR-CA in cases of acute

of cardioembolic events is substantial. 4,10

heart failure precipitated by arrhythmias, especially

renal

impairment

and

heart

failure.

Two of our patients underwent cardioversion to

when there are signs of restrictive physiology, lack of

normal sinus rhythm. However, only 1 patient ach-

ventricular dilation on echocardiogram, and discor-

ieved rapid reversal of cardiogenic shock; the other

dant low voltage on ECG.

was dependent on inotropic support and eventually
required heart transplantation. This heterogeneity
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F I G U R E 5 Visual Depiction of Echocardiographic Findings in Transthyretin Cardiac Amyloidosis and the Precipitation of Cardiogenic Shock by Atrial Arrhythmias

LV ¼ left ventricular. Figure created using Biorender.

REFERENCES
1. Kim MM, Kolseth CM, Carlson D, Masri A. Clinical management of amyloid cardiomyopathy.
Heart Fail Rev. 2022;27:1549–1557. https://doi.

Predictors, prevalence, and efﬁcacy of rhythm
control strategies. J Am Coll Cardiol EP.
2020;6(9):1118–1127.

org/10.1007/s10741-021-10159-w
2. Mints YY, Doros G, Berk JL, Connors LH,
Ruberg FL. Features of atrial ﬁbrillation in wildtype transthyretin cardiac amyloidosis: A systematic review and clinical experience. ESC Heart Fail.
2018;5(5):772–779.
3. Sanchis K, Cariou E, Colombat M, et al. Atrial
ﬁbrillation and subtype of atrial ﬁbrillation in
cardiac amyloidosis: Clinical and echocardiographic features, impact on mortality. Amyloid.
2019;26(3):128–138.
4. Donnellan E, Wazni OM, Hanna M, et al. Atrial
ﬁbrillation in transthyretin cardiac amyloidosis:

8. Hartnett J, Jaber W, Maurer M, et al. Electrophysiological manifestations of cardiac amyloidosis. J Am Coll Cardiol CardioOnc. 2021;3(4):506–
515.

5. Gonzalez-Duarte A, Valdés-Ferrer SI, CantúBrito C. Characteristics and natural history of
autonomic involvement in hereditary ATTR
amyloidosis: A systematic review. Clin Auton Res.
2019;29(Suppl 1):1–9.
6. Giancaterino S, Urey MA, Darden D, Hsu JC.
Management of arrhythmias in cardiac amyloidosis. J Am Coll Cardiol EP. 2020;6(4):351–361.
7. Cheung CC, Roston TM, Andrade JG,
Bennett MT, Davis MK. Arrhythmias in cardiac
amyloidosis: Challenges in risk stratiﬁcation and
treatment. Can J Cardiol. 2020;36(3):416–423.

9. El-Am EA, Dispenzieri A, Melduni RM, et al.
Direct current cardioversion of atrial arrhythmias
in adults with cardiac amyloidosis. J Am Coll Cardiol. 2019;73:589–597.
10. Feng D, Syed IS, Martinez M, et al. Intracardiac
thrombosis and anticoagulation therapy in cardiac
amyloidosis. Circulation. 2009;119(18):2490–2497.

KEY WORDS atrial arrythmias, cardiac
amyloid, restrictive physiology, transthyretin
cardiac amyloidosis

